Page 202 - 2021_06-Haematologica-web

H. Larose et al.
28.Chun S, Fay JC. Identification of deleterious
mutations within three human genomes.
Genome Res. 2009;19(9):1553-1561.
29. Schwarz JM, Cooper DN, Schuelke M, Seelow D. Mutationtaster2: mutation pre- diction for the deep-sequencing age. Nat
Methods. 2014;11(4):361-362.
30.Choi Y, Sims GE, Murphy S, Miller JR,
Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688.
31.Mason CC, Khorashad JS, Tantravahi SK, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016;30(4):906-913.
32.Ljungström V, Cortese D, Young E, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127(8):1007-1016.
33.Neumann M, Vosberg S, Schlee C, et al. Mutational spectrum of adult T-ALL. Oncotarget. 2015;6(5):2754-2766.
34.Kohsaka S, Shukla N, Ameur N, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46(6):595-600.
35.Martin D, Abba MC, Molinolo AA, et al. The head and neck cancer cell oncogenome: a platform for the develop- ment of precision molecular therapies. Oncotarget. 2014;5(19):8906-8923.
36.Luca VC, Kim BC, Ge C, et al. Notch- Jagged complex structure implicates a catch bond in tuning ligand sensitivity. Science. 2017;355(6331):1320-1324.
37.Menotti M, Ambrogio C, Cheong T-C, et al. Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lym- phoma. Nat Med. 2019;25(1):130-140.
38.Choi SH, Severson E, Pear WS, et al. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia. PLoS One. 2017;12(10):e0185762.
39. Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, et al. Synergistic antileukemic thera- pies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A. 2017;114(8):2006-2011.
40.Wang H, Zou J, Zhao B, et al. Genome- wide analysis reveals conserved and diver- gent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(36):14908-14913.
41.Locatelli MA, Aftimos P, Dees EC, et al. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with
docetaxel in patients with advanced triple- negative breast cancer. Oncotarget. 2017;8(2):2320-2328.
42.Turturro F, Frist AY, Arnold MD, Seth P, Pulford K. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1). Oncogene. 2001;20(33):4466- 4475.
43. Kamstrup MR, Ralfkiaer E, Skovgaard GL, Gniadecki R. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lympho- proliferative disorders. Br. J. Dermatol. 2008;158(4):747-753.
44.Meeks HD, Song H, Michailidou K, et al. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. J Natl Cancer Inst. 2015;108(2): djv315.
45. Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol. 2006;301:259-281.
46.Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-depen- dent mechanisms. Cell Signal. 2007;19(4):740-747.
47.Aster JC, Blacklow SC, Pear WS. Notch sig- nalling in T-cell lymphoblastic leukaemia/lymphoma and other haemato- logical malignancies. J Pathol. 2011;223(2): 262-273.
48.Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151-1157.
49.Wang NJ, Sanborn Z, Arnett KL, et al. Loss- of-function mutations in Notch receptors in cutaneous and lung squamous cell carcino- ma. Proc Natl Acad Sci U S A. 2011;108(43):17761-17766.
50.Vollbrecht C, Mairinger FD, Koitzsch U, et al. Comprehensive analysis of disease-relat- ed genes in chronic lymphocytic leukemia by multiplex PCR-based next generation sequencing. PLoS One. 2015;10(6): e0129544.
51.Athanasakis E, Melloni E, Rigolin GM, et al. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget. 2014;5(24):12635-12645.
52.Rebay I, Fleming RJ, Fehon RG, et al. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: impli-
cations for notch as a multifunctional recep-
tor. Cell. 1991;67(4):687-699.
53.Stanley P, Okajima T. Roles of glycosylation
in notch signaling. Curr Top Dev Biol.
2010;92:131-164.
54. Haines N, Irvine KD. Glycosylation regu-
lates Notch signalling. Nat Rev Mol Cell
Biol. 2003;4(10):786-797.
55. Pakkiriswami S, Couto A, Nagarajan U,
Georgiou M. Glycosylated Notch and can-
cer. Front Oncol. 2016;6:37.
56.Rand MD, Grimm LM, Artavanis-Tsakonas
S, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol. 2000;20(5):1825-1835.
57.Rust R, Visser L, Van Der Leij J, et al. High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplas- tic large cell lymphoma. Br J Haematol. 2005;131(5):596-608.
58.Dang Q, Chen L, Xu M, et al. The γ-secre- tase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lym- phoma cell apoptosis. Cell Signal. 2019;59:76-84.
59.Hudson S, Wang D, Middleton F, et al. Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes. Pediatr Blood Cancer. 2018;65(8):e27094.
60.Larose H, Burke GAA, Lowe EJ, Turner SD. From bench to bedside: the past, present and future of therapy for systemic paedi- atric ALCL, ALK. Br J Haematol. 2019;185 (6):1043-1054.
61.Habets RA, de Bock CE, Serneels L, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med. 2019;11(494): eaau6246.
62.Papayannidis C, DeAngelo DJ, Stock W, et al. A phase 1 study of the novel gamma- secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015;5:e350.
63.Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblas- tic leukemia. Mol Cancer Ther. 2012;11(7): 1565-1575.
64.Wei P, Walls M, Qiu M, et al. Evaluation of selective gamma-secretase inhibitor PF- 03084014 for its antitumor efficacy and gas- trointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010;9(6): 1618-1628.
1704
haematologica | 2021; 106(6)